Description: Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. Its lead ddCAR product candidate is CART-ddBCMA, which is in Phase 1 clinical development for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). The company is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Home Page: arcellx.com
ACLX Technical Analysis
25 West Watkins Mill Road
Gaithersburg,
MD
20878
United States
Phone:
240 327 0603
Officers
| Name | Title |
|---|---|
| Mr. Rami Elghandour | Chairman, CEO & Pres |
| Mr. Neeraj P. Teotia | Chief Commercial Officer |
| Dr. Christopher R. Heery M.D. | Chief Medical Officer |
| Ms. Michelle Lim Gilson | Chief Financial Officer |
| Mr. Michael Dombeck M.B.A. | Chief Operating Officer |
| Mr. Narinderjeet Singh M.S. | Chief Technical Officer |
| Mr. David Tice Ph.D. | Chief Scientific Officer |
| Ms. Myesha Lacy | VP of Investor Relations |
| Ms. Maryam Abdul-Kareem J.D., M.S. | Gen. Counsel |
| Ms. Kate Aiken | Chief People Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.1247 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-02-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 78 |